A Phase Ia, single center, double-blind, randomized, placebo-controlled trial to investigate the safety, tolerability, and pharmacokinetics of single ascending doses of iMPV in healthy volunteers
Latest Information Update: 11 Jan 2023
At a glance
- Drugs Murepavadin (Primary) ; Murepavadin (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions; First in man
Most Recent Events
- 09 Jan 2023 Results published in a Spexis media release.
- 09 Jan 2023 Status changed from recruiting to completed, according to a Spexis media release.
- 06 Sep 2022 According to a Spexis media release, enrollment of this Phase 1 trial of inhaled murepavadin in healthy volunteers continues with top-line results expected by year-end 2022